Hernia Mesh Lawsuit: Where Four Separate MDLs Stand

Most mass torts on this site involve a single manufacturer and a single MDL moving through one procedural track. Hernia mesh litigation is different: four separate manufacturers, four separate federal proceedings, and four genuinely different postures as of this writing — one largely settled, one just tested by its first jury verdict, and two still working through confidential or newly-funded settlement processes.

Quick answer: Hernia mesh lawsuits allege polypropylene mesh was defectively designed and inadequately warned against, causing chronic pain, adhesion, migration, erosion, bowel obstruction and the need for revision surgery. Four manufacturers face separate federal litigation: Bard/Davol (MDL No. 2846, Southern District of Ohio) has largely settled roughly 38,000 cases for over $1 billion, with payments still processing; Covidien (MDL No. 3029, District of Massachusetts) just saw its first bellwether trial end in an $88 million verdict in August 2026; Ethicon reached a confidential global settlement; and Atrium has a court-approved Qualified Settlement Fund of roughly $66 million. Which manufacturer made your specific mesh determines which of these four completely different situations actually applies to you.

What the Litigation Alleges

Hernia repairs using polypropylene mesh are alleged to have been defectively designed and manufactured, with manufacturers failing to adequately warn surgeons and patients of known risks. The core scientific allegation: polypropylene can degrade inside the body and provoke a chronic inflammatory response, leading to a well-documented list of complications — chronic pain, infection, bowel obstruction, adhesion to internal organs, organ perforation, mesh migration, mesh erosion, fistula formation, hernia recurrence, and the need for revision surgery to remove or replace the mesh entirely. Manufacturers dispute the extent to which these complications reflect a genuine product defect as opposed to inherent, disclosed surgical risk.

Four Manufacturers, Four Separate Proceedings

This is the single most important structural fact about this litigation: there is no one hernia mesh MDL. See our explainer on how mass tort litigation actually works for what an MDL is generally; here, four exist in parallel:

• Davol, Inc. / C.R. Bard, Inc. — consolidated as MDL No. 2846, In re: Davol, Inc./C.R. Bard, Inc. Polypropylene Hernia Mesh Products Liability Litigation, in the U.S. District Court for the Southern District of Ohio before Judge Edmund A. Sargus. This is the largest and most procedurally advanced of the four dockets.
• Covidien (a Medtronic subsidiary) — a separate proceeding, MDL No. 3029, in the U.S. District Court for the District of Massachusetts before Judge Patti B. Saris.
• Atrium Medical Corporation — its own, smaller federal MDL, now moving toward resolution through a court-approved settlement fund.
• Ethicon, Inc. (a Johnson & Johnson subsidiary) — its own federal proceeding, now resolved through a confidential global settlement.

A ruling, verdict, or settlement in any one of these four proceedings has no automatic effect on the other three. Identifying which manufacturer’s product was actually implanted is the first, and most consequential, fact-finding step in any individual case.

Bard: The Most Advanced Docket

Bard’s parent company, Becton Dickinson, agreed in October 2024 to settle roughly 38,000 hernia mesh lawsuits in a deal reported at over $1 billion — by far the largest resolution among the four manufacturers. As of this writing, individual payments are still being processed rather than fully completed. A global settlement agreement being reached is a major milestone, but it is not the same as every eligible claimant having actually received payment — the same distinction our guide to filing a claim in a class action or mass tort settlement covers generally, and one worth confirming directly with the settlement administrator rather than assuming from the headline figure.

Covidien: A Bellwether Verdict That Just Landed

Covidien’s MDL took a different path. Rather than a global settlement, the docket proceeded to its first bellwether trial, which began in mid-July 2026 and concluded in early August 2026 with an $88 million verdict for the plaintiff. As our guide to mass tort litigation explains, a bellwether trial is specifically selected to test how a jury values a representative set of claims — the verdict does not automatically bind the more than 2,400 other active cases in this MDL, but a result this size carries real, practical weight on how both sides value the remaining docket going forward, including whether Covidien now moves toward a broader settlement of its own.

Ethicon and Atrium: Two Different, Less Public Paths to Resolution

Ethicon has agreed to a confidential global settlement — the terms have not been publicly disclosed, which is common in this kind of resolution but means a specific claimant cannot simply look up a published figure to know what to expect. Atrium’s docket has instead moved through a court-approved Qualified Settlement Fund, reportedly funded at approximately $66 million, structured to begin resolving claims against that specific manufacturer. Neither development means every pending claim against these two companies has already been paid — the mechanics of an individual claim within each still need to be confirmed directly.

Building an Individual Claim

• Surgical records identifying the exact mesh product and manufacturer — frequently the single most important document, since a patient’s own memory of “which mesh” is rarely reliable and multiple manufacturers’ products can look and be described similarly
• Records of the complication itself — imaging showing migration or erosion, revision surgery operative reports, treatment records for chronic pain, infection or bowel obstruction
• A clear timeline connecting the original implant date to when the complication was diagnosed, since a claim’s deadline can turn on a discovery-rule accrual date rather than the original surgery date

Practical Steps

1. Obtain your surgical records and identify the exact mesh product and manufacturer before assuming which of the four proceedings, if any, applies to you.
2. Do not assume a settlement in one manufacturer’s docket resolves a claim against a different one — these are four separate legal proceedings with four separate outcomes.
3. If your product was made by Bard, confirm your claim’s status directly with the settlement administrator, since payments are still processing rather than complete.
4. If your product was made by Covidien, understand that the August 2026 bellwether verdict is informative but not binding on your own case’s value.
5. Gather complete records of the complication and any revision surgery, since these establish both the injury and the timeline a deadline analysis depends on.
6. Consult an attorney handling hernia mesh claims specifically, given how much the right next step depends on identifying the correct manufacturer among four separate dockets.

Sources & Further Reading

• U.S. District Court, Southern District of Ohio — docket for MDL No. 2846, In re: Davol, Inc./C.R. Bard, Inc. Polypropylene Hernia Mesh Products Liability Litigation
• U.S. District Court, District of Massachusetts — docket for MDL No. 3029, the Covidien hernia mesh litigation
• Court filings on the Atrium Medical Qualified Settlement Fund and the Ethicon confidential global settlement
• See our guides to defective product claims and the three liability theories for the design-defect and failure-to-warn framework this litigation is built on, how mass tort litigation actually works for how an MDL and a bellwether trial function generally, and filing a claim in a class action or mass tort settlement for what happens procedurally once a settlement like Bard’s is reached but still being paid out